Oragenics Inc
OGEN1.190USD
-0.020-1.65%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
979.28KMarket Cap
LossP/E TTM
More Details of Oragenics Inc Company
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
Company Info
Ticker SymbolOGEN
Company nameOragenics Inc
IPO dateJul 09, 2003
CEOMs. Janet Huffman
Number of employees3
Security typeOrdinary Share
Fiscal year-endJul 09
Address1990 Main Street
CitySARASOTA
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code34236
Phone18132867900
Websitehttps://www.oragenics.com/
Ticker SymbolOGEN
IPO dateJul 09, 2003
CEOMs. Janet Huffman
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
1.16K
--
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Executive Chairman of the Board
Executive Chairman of the Board
849.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Dr. James Kelly, M.D.
Dr. James Kelly, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Mr. Tirth T. Patel
Mr. Tirth T. Patel
Vice President
Vice President
--
--
Dr. William (Frank) Peacock, M.D.
Dr. William (Frank) Peacock, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Ms. Natasha Giordano
Ms. Natasha Giordano
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
1.16K
--
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Executive Chairman of the Board
Executive Chairman of the Board
849.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Dr. James Kelly, M.D.
Dr. James Kelly, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Five Narrow Lane LP
1.99%
Clear Street LLC
1.71%
BofA Global Research (US)
0.38%
Cassidy (Bruce A Sr)
0.29%
Morgan Stanley & Co. LLC
0.29%
Other
95.35%
Shareholders
Shareholders
Proportion
Five Narrow Lane LP
1.99%
Clear Street LLC
1.71%
BofA Global Research (US)
0.38%
Cassidy (Bruce A Sr)
0.29%
Morgan Stanley & Co. LLC
0.29%
Other
95.35%
Shareholder Types
Shareholders
Proportion
Research Firm
2.39%
Corporation
2.00%
Individual Investor
0.41%
Investment Advisor
0.09%
Investment Advisor/Hedge Fund
0.06%
Hedge Fund
0.02%
Other
95.03%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
52
24.58K
2.99%
-32.18K
2025Q1
54
104.53K
39.81%
+67.24K
2024Q4
61
3.11M
25.46%
+2.05M
2024Q3
59
1.22M
18.08%
+226.05K
2024Q2
58
1.45M
24.58%
+674.78K
2024Q1
57
1.51M
26.60%
+861.00K
2023Q4
59
1.13M
28.10%
+795.74K
2023Q3
58
266.28K
10.68%
+19.84K
2023Q2
53
93.56K
4.68%
-159.82K
2023Q1
59
99.61K
5.08%
-139.03K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cassidy (Bruce A Sr)
11.82K
1.44%
+3.00
+0.03%
Mar 21, 2025
UBS Financial Services, Inc.
200.00
0.02%
+32.00
+19.05%
Mar 31, 2025
Telling (Frederick W)
1.16K
0.14%
--
--
Mar 21, 2025
Koski (Robert C)
931.00
0.11%
--
--
Mar 21, 2025
Dunton (Alan W)
854.00
0.1%
--
--
Mar 21, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
Date
Type
Ratio
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
Dec 23, 2022
Merger
60→1
